RegeneRx Biopharmaceuticals, Inc. filed its 10-K on Apr 11, 2023 for the period ending Dec 31, 2022. In this report its auditor, CohnReznick LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0014 USD | 0.00% | 0.00% | +16.67% |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 2.11K | |
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-12.32% | 33.03B | |
+54.82% | 24.68B | |
-17.39% | 15.12B | |
-9.14% | 12.81B | |
-10.48% | 11.79B | |
-42.45% | 11.64B | |
+7.27% | 8.9B |
- Stock Market
- Equities
- RGRX Stock
- News RegeneRx Biopharmaceuticals, Inc.
- RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt